Delving into the Latest Updates on Firebrick Pharma Ltd. with Synapse

概览

关联

5

项与 Firebrick Pharma Ltd. 相关的临床试验

ACTRN12621000604808

/ Completed临床3期

Confirmatory Phase III study of Nasodine Nasal Spray (povidone-iodine 0.5%) as a symptomatic treatment for early stage common cold in the natural setting.

开始日期2022-05-03

申办/合作机构

Firebrick Pharma Ltd.

ACTRN12621000034831

/ Completed早期临床1期

Virucidal pilot study of Nasodine® (povidone-iodine 0.5%) nasal spray in people in South Africa with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.

开始日期2020-11-20

申办/合作机构

Firebrick Pharma Ltd.

[+1]

ACTRN12620000470998

/ Withdrawn早期临床1期

Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.

开始日期2020-04-20

申办/合作机构

Firebrick Pharma Ltd.

100 项与 Firebrick Pharma Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Firebrick Pharma Ltd. 相关的专利（医药）

登录后查看更多信息

1

项与 Firebrick Pharma Ltd. 相关的文献（医药）

2024-03-01·Diabetes

Liver-Selective Imidazolopyrazine Mitochondrial Uncoupler SHD865 Reverses Adiposity and Glucose Intolerance in Mice

Article

作者: Wathier, Michel ; Philp, Ashleigh M ; Chen, Sing-Young ; Alexopoulos, Stephanie J ; Bayliss, Douglas A ; Philp, Andrew ; Harris, Thurl E ; Li, Catherine ; Byrne, Frances L ; Li, Keyong ; Vancuylenburg, Calum S ; Beretta, Martina ; Hoehn, Kyle L ; Lee, Brendan ; Hargett, Stefan R ; Shah, Divya P ; Santos, Webster L ; Turner, Nigel ; Cermak, Jennifer M ; Santiago-Rivera, José A ; Olzomer, Ellen M ; Dai, Yumin ; Tucker, Simon P

Excess body fat is a risk factor for metabolic diseases and is a leading preventable cause of morbidity and mortality worldwide. There is a strong need to find new treatments that decrease the burden of obesity and lower the risk of obesity-related comorbidities, including cardiovascular disease and type 2 diabetes. Pharmacologic mitochondrial uncouplers represent a potential treatment for obesity through their ability to increase nutrient oxidation. Herein, we report the in vitro and in vivo characterization of compound SHD865, the first compound to be studied in vivo in a newly discovered class of imidazolopyrazine mitochondrial uncouplers. SHD865 is a derivative of the furazanopyrazine uncoupler BAM15. SHD865 is a milder mitochondrial uncoupler than BAM15 that results in a lower maximal respiration rate. In a mouse model of diet-induced adiposity, 6-week treatment with SHD865 completely restored normal body composition and glucose tolerance to levels like those of chow-fed controls, without altering food intake. SHD865 treatment also corrected liver steatosis and plasma hyperlipidemia to normal levels comparable with chow-fed controls. SHD865 has maximal oral bioavailability in rats and slow clearance in human microsomes and hepatocytes. Collectively, these data identify the potential of imidazolopyrazine mitochondrial uncouplers as drug candidates for the treatment of obesity-related disorders.Article Highlights

100 项与 Firebrick Pharma Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Firebrick Pharma Ltd. 相关的转化医学

登录后查看更多信息